ChemicalBook > CAS DataBase List > Cisplatin

Cisplatin

History of discovery Pharmacological effects Adverse reactions and side effects

Product Name: Cisplatin
CAS No.: 15663-27-1
Chemical Name: Cisplatin
Synonyms: cddp;cpdd;CIS-PLATINUM;cis-dichlorodiammineplatinum;CIS-DIAMMINEPLATINUM(II) DICHLORIDE;CPDC;cacp;PLATINOL;CISPLATIIN;cisplatine
CBNumber: CB9236183
Molecular Formula: Cl2H6N2Pt
Formula Weight: 300.04
MOL File: 15663-27-1.mol

Less

Cisplatin Property

Melting point:: 270 °C (lit.)
Density: 3,7 g/cm³
bulk density: 850kg/m3
storage temp.: 2-8°C
solubility: Soluble in DMF. Insoluble in most common solvents
form: crystalline
color: yellow
Water Solubility: <0.1 g/100 mL at 19 ºC
Merck: 14,2317
Exposure limits: ACGIH: TWA 0.002 mg/m3
NIOSH: IDLH 4 mg/m3; TWA 0.002 mg/m3
Stability:: Stable. Incompatible with oxidizing agents, aluminium, antioxidants.
CAS DataBase Reference: 15663-27-1(CAS DataBase Reference)
IARC: 2A (Vol. 26, Sup 7) 1987, 1 (Vol. 76, 100A) 2012
EPA Substance Registry System: Cisplatin (15663-27-1)

Less

Safety

Hazard Codes: T
Risk Statements: 45-25-41-60-46-42/43-36/37/38
Safety Statements: 53-26-39-45-99-36/37/39-22
RIDADR: UN 3288 6.1/PG 2
WGK Germany: 3
RTECS: TP2455000
F: 10-21
TSCA: Yes
HS Code: 2843 90 90
HazardClass: 6.1(a)
PackingGroup: II
Hazardous Substances Data: 15663-27-1(Hazardous Substances Data)
Toxicity: LD50 in guinea pigs: 9.7 mg/kg i.p. (Fleishman)

Less

Hazard and Precautionary Statements (GHS)

Symbol(GHS)

Signal word

Danger

Hazard statements

H300Fatal if swallowed

H315Causes skin irritation

H317May cause an allergic skin reaction

H319Causes serious eye irritation

H334May cause allergy or asthma symptoms or breathing difficulties if inhaled

H335May cause respiratory irritation

H350May cause cancer

Precautionary statements

P201Obtain special instructions before use.

P280Wear protective gloves/protective clothing/eye protection/face protection.

P301+P310IF SWALLOWED: Immediately call a POISON CENTER or doctor/physician.

P302+P352IF ON SKIN: wash with plenty of soap and water.

P305+P351+P338IF IN EYES: Rinse cautiously with water for several minutes. Remove contact lenses, if present and easy to do. Continuerinsing.

Less

N-Bromosuccinimide Price

Sigma-Aldrich

Product number: C2210000
Product name: Cisplatin
Purity: European Pharmacopoeia (EP) Reference Standard
Packaging: 100 mg
Price: $236
Updated: 2025/07/31

Sigma-Aldrich

Product number: BP809
Product name: Cisplatin
Purity: British Pharmacopoeia (BP) Reference Standard
Packaging: 100MG
Price: $263
Updated: 2025/07/31

Sigma-Aldrich

Product number: 8.24510
Product name: cis-Platinum (65% Pt)
Purity: for synthesis
Packaging: 100MG
Price: $68.2
Updated: 2025/07/31

Sigma-Aldrich

Product number: 8.24510
Product name: cis-Platinum (65% Pt)
Purity: for synthesis
Packaging: 500MG
Price: $260
Updated: 2025/07/31

Sigma-Aldrich

Product number: 232120
Product name: Cisplatin
Packaging: 50mg
Price: $129
Updated: 2025/07/31

Less

Cisplatin Chemical Properties,Usage,Production

History of discovery

Cisplatin is currently one of the most commonly used drugs used in combination chemotherapy with its chemical full name being cis-dichlorodiamineplatinum. It belongs to inorganic metal complexes. After the dissociation of the chlorine atom, it can be cross-linked with the DNA of the cancer cell DNA, thereby destroying the DNA function. It can form intra-strand or inter-strand crosslink with the DNA and may also form a cross-link with DNA and protein, and can inhibit cell mitosis, belonging to cell cycle non-specific drugs. In addition to its anti-cancer effect, it is still capable of inhibiting lymphocyte transformation and having immunosuppression effect and thus can be used as the metal complex-class anti-cancer drugs.
In 1844, it had been first successfully developed by the French chemist Mario Rampini and has been ever called Rampini's salt. It appears as an orange crystal. It has a small solubility (being 0.252 g/ 100 g of water at 25 ℃) and can be produced through the reaction between tetrachloro platinum (II) solution of potassium and ammonia.
In 1891, the modern founder of coordination chemistry, Werner, starting from the study of this class of compounds, had successfully established a complex theory, and clarified the cis structure of the Rampini's salt.
It was not until 1965 that the anticancer activity of cisplatin was found by Rosenberg and his colleagues from University of Michigan USA. When studying the effect of the electric filed on the growth of E. coli, they found that when putting into the metallic platinum to the medium containing ammonium chloride and then sending through 2 ampere for two hours, the reproduction of E. coli was inhibited. Further studies had showed that this is the effect of the cisplatin which is the product produced through the chemical reaction between the ammonia chloride and the platinum ion produced by electrolytic oxidation in the electrode. Rosenberg thought that given that cisplatin can prevent cell division, it should also have anticancer activity. Through the anti-cancer test, it has been proven that there is a good anti-cancer effect of cisplatin, drawing broad interest in metal complexes pharmacology. People had organized international cooperation research on chemistry, biology and medical field, finally enabling the successful applications of cisplatin in the treatment of cancer.
In December 1978, the US Food and Drug Administration had approved cisplatin for clinical application and make it as a commodity to supply the market. It has properties such as broad anti-tumor spectrum and being effective in treating hypoxic cells. However, it has toxicity to the kidneys, nervous system and pancreas. Modern pharmacology has classified this product as antineoplastic agents.

Pharmacological effects

Cisplatin is the most commonly used metal platinum complexes with the platinum atoms containing in the molecule being important for its anti tumor effect. However, it is also effective in the form of cis while being invalid in the Trans form. It can be cross-linked to DNA strand, showing cytotoxicity. After its dissolution inside the human body, it doesn’t need carrier transport in the body while being able to penetrate through the charged cell membrane. Owing to the low intracellular chloride concentration (4mmol /L), chloride ions are replaced by the water with the charge being positive which has a similar effect as bifunctional group of alkylating agent. It can combine with the nuclear DNA bases, forming three forms of cross-linking, resulting in DNA damage, further destroying DNA replication and transcription with the capability of inhibiting the synthesis of RNA and proteins at high concentrations as well. Cisplatin is characterized by broad anti-cancer spectrum, being effective in treating hypoxic cells and strong action. It has been widely used in the treatment of testicular cancer, ovarian cancer, uterine cancer, bladder cancer, cervical cancer, prostate cancer and brain cancer with significant efficacy. However, cisplatin has certain toxicity when being used in the treatment of cancer and thus being able to cause side effects. Therefore, it is necessary to continuously identify analogues of cisplatin with less toxicity and clinical effect being similar as cisplatin. So far scientists from various countries have been synthesized and tested thousands of cisplatin-related metal complexes and have developed the second-generation anti-cancer platinum complexes with carboplatin being the representative. The third generation anticancer metal complexes have also been identified with titanocene dichloride as the representative. These compounds have nothing to do with cisplatin from the chemical perspective but they have relative good efficacy in treating some kinds of cancer which can be hardly treated by cisplatin without doing harm to the kidney function. Now people in this area are continuing extensive research with the efforts majorly lining in exploring the anticancer mechanism of metal complexes at the molecular level. China has already started producing the goods of cisplatin and has carried out research in this area.
Cisplatin belongs to non-specific cell cycle drugs with cytotoxicity. Since the proliferation and synthesis rate of cancer cells is more rapid than normal cells, the cancer cell is more sensitive than normal cell to the toxic effects of this product. It can inhibit the DNA replication of cancer cell, and destroy the structure of the cell membrane. It has a strong broad-spectrum anti-cancer effect. It can be used for the treatment of ovarian cancer, prostate cancer, testicular cancer and other genitourinary malignancies with an excellent efficacy. When being used in combination with vincristine, cyclophosphamide and 5-fluorouracil, it has an excellent efficacy in the treatment of malignant lymphoma, breast cancer, carcinoma of head and neck squamous cell, thyroid cancer, and osteosarcoma, etc. Cisplatin, in combination with radiotherapy, can be used in the treatment for patients with advanced non-small cell lung cancer; nasopharyngeal cancer and esophageal cancer with prominent effect. It also has certain efficacy in the treatment of liver cancer and soft tissue sarcoma. Cisplatin, as a strong accumulative drug, is easy to produce renal toxicity with the gastrointestinal reactions being relatively common with neutropenia occurring in some patients but can be restored after the withdrawal of drugs for 7 to 14 days.
In addition, the DNA damage effect of this product can also possibly change the antigenicity in the nucleus or the cell surface so that the original hidden surface antigen is exposed, stimulating the immune suppression of antibodies and exert their cytotoxic effects.
This information is edited by Xiongfeng Dai from Chemicalbook.

Adverse reactions and side effects

Upon being subject to one-time injection of cisplatin for 50mg/m2, 25% to 30% of patients can get azotemia. Upon a larger dose and continuous medication, it can have serious and long-lasting kidney toxicity, manifested as tubular swelling, degenerative disease, elevated level of serum urea nitrogen, decreased creatinine clearance, hematuria, proteinuria, and even uremia.
It may have mild to moderate bone marrow toxicity whose degree depends on the amount of cisplatin. Anemia is common and may be accompanied with hemolysis. The patients can get severe nausea and vomiting which often appears at the beginning of treatment within 1h, lasting 8~12 h. The patients can administrate dexamethasone, ondansetron and diazepam to reduce the reaction.
It can cause malignant renal toxicity and is prone to occur at patients free from hydration and patients of diuretic therapy.
Combination with renal toxic antibiotics may increase the risk of enhancing acute renal failure.
It can commonly cause high-frequency hearing loss, and occasionally significant hearing loss. Tinnitus can occur at rare cases.
There may be significant symptoms of hyponatremia, hypomagnesemia, hypocalcemia, and hypokalemia which may occur in a few days after treatment.
After several times of administration can cause allergic reaction which can occur within minutes after administration, being manifested as facial edema, wheezing, tachycardia, etc. The patients should be quickly subject to anti-allergy measures such as antihistamine and adrenocorticotropic hormone.
There may be peripheral nerve toxicity. Hyperuricemia occurs rarely. There are occasional symptoms of orthostatic hypotension.

Description

Cisplastin is an non-organic platinum-containing drug with alkylating properties. It causes cross-linking of DNA and RNA chains. In particular, it has been shown, that cisplastin, like other alkylating agents, bind primarily at N7 of two neighboring deoxyguanylates to DNA, which inhibits its replication. It is only used intravenously. It is highly reactive with carcinomas of the testicles, ovaries, heat, neck, spleen, lungs, and so on.

Chemical Properties

Cisplatin is a white powder or yellow crystalline solid with the melting point 268-272°C (decomposition). It is slightly soluble in water and easily soluble in dimethylformamide. In aqueous solution, it can be gradually transformed into trans-and hydrolysis.

Originator

Blastolem,Lemery,Mexico

Uses

Cisplatin is a cytostatic agent and it is used to treat various cancer types, including cancer of ovary, testis, lung, head, neck, bladder, neuroblastoma, and nephroblastoma, and Hodgkin’s disease and non-Hodgkin lymphoma.

Uses

cisplatin is a platinum complex, cis-[PtCl2(NH3)2], used in cancer treatmentto inhibit the growth oftumours. It acts by binding betweenstrands of DNA.

Definition

ChEBI: Cisplatin is a diamminedichloroplatinum compound in which the two ammine ligands and two chloro ligands are oriented in a cis planar configuration around the central platinum ion. An anticancer drug that interacts with, and forms cross-links between, D A and proteins, it is used as a neoplasm inhibitor to treat solid tumours, primarily of the testis and ovary.

Production Methods

Cisplatin is obtained by the method described by Kauffman and Cowan, in which potassium(II) tetrachloroplatinate is treated with buffered aqueous ammonia solution. Pure cisplatin is obtained by recrystallization from dilute hydrochloric acid.

Indications

Cisplatin (Platinol) is an inorganic coordination complex with a broad range of antitumor activity. It is especially useful in the treatment of testicular and ovarian cancer. It binds to DNA at nucleophilic sites, such as the N7 and O6 of guanine, producing alterations in DNA structure and inhibition of DNA synthesis. Adjacent guanine residues on the same DNA strand are preferentially cross-linked. This platinating activity is analogous to the mode of action of alkylating agents. Cisplatin also binds extensively to proteins. It does not appear to be phase specific in the cell cycle.

Manufacturing Process

The synthesis proceeds dy reduction of potassium hexachlorplatinate with hydrazine to give potassium tetrachloroplatinate. This is converted to potassium tetraiodoplatinate by treatment with potassium iodide and then reacted with 6 M ammonium hydroxide to give crystals of cisplatin

Therapeutic Function

Antitumor

General Description

administrationin the treatment of a wide variety of cancers includingnon-Hodgkin’s lymphoma, bladder cancer, ovarian cancer,testicular cancer, and cancers of the head and neck. A liposomalform is also available as well as an injectable collagenmatrix gel containing cisplatin. Compared with other platins,cisplatin is the most reactive and therefore the most effectivein platinating DNA. After IV administration, the agent iswidely distributed, highly protein bound (90%), and concentratesin the liver and kidney. After infusion, covalent attachmentto plasma proteins occurs such that after 4 hours, 90%of drug is protein bound. The elimination of platinum fromthe blood is a slow process with a terminal elimination halflifeof 5 to 10 days. Metabolism involves aquation, which occursto a greater extent once distribution out of the plasmahas occurred. Additional metabolites have been seen resultingfrom reaction with glutathione and cysteine. The greaterreactivity of cisplatin gives rise to significant toxicitiescompared with other platins. These include dose-limitingnephrotoxicity, which normally presents as elevated bloodurea nitrogen (BUN) and creatinine. This effect is cumulativeupon repeated dosing and may progress further to necrosis,altered epithelial cells, cast formation, and thickening ofthe tubular basement membranes but is generally reversibleupon discontinuation of drug treatment. Sodium thiosulfatemay be given to reduce the nephrotoxicity. Neurotoxicitymay also be dose limiting, normally presenting initially asnumbness but may progress to seizure. Other adverse effectsinclude myelosuppression, nausea, vomiting, alopecia,ototoxicity, ocular toxicity, azoospermia, impotence, myocardialinfarction, thrombotic events, and inappropriatesecretion of antidiuretic hormone.

General Description

An anticancer drug. Orange-yellow to deep yellow solid or powder.

Air & Water Reactions

Insoluble in water.

Reactivity Profile

Cisplatin is incompatible with oxidizing agents. Cisplatin is also incompatible with aluminum. Cisplatin may react with sodium bisulfite and other antioxidants.

Fire Hazard

Flash point data for Cisplatin are not available; however, Cisplatin is probably combustible.

reaction suitability

core: platinum
reagent type: catalyst

Pharmaceutical Applications

CDDP, also referred to as cisplatinum or cisplatin, is a yellow powder and has found widespread use a chemotherapeutic agent.

Biological Activity

Cisplatin is a platinum-containing compound that acts as a DNA-crosslinking agent and interferes with replication and transcription, culminating in apoptosis. It forms intra- and interstrand crosslinks with DNA with intrastrand guanine-to-guanine or guanine-to-alanine links accounting for the majority of DNA binding. Cisplatin halts the cell cycle at the G2/M phase in vitro and is active against murine tumors transplanted into mice and in mouse xenograft models, including a reduction in tumor growth in a model of squamous cell carcinoma of the head and neck when administered at doses ranging from 7.5 to 12.5 mg/kg. Cisplatin also inhibits the RecA recombinase of M. tuberculosis (IC50 = 2 μM), blocking protein splicing and cell growth. Formulations containing cisplatin have been used, alone and in combination therapy, in the treatment of a variety of cancers.

Biochem/physiol Actions

Potent platinum-based antineoplastic agent. Forms cytotoxic adducts with the DNA dinucleotide d(pGpG), inducing intrastrand cross-links.

Mechanism of action

Cisplatin shows biphasic plasma decay with a distribution phase half-life of 25 to 49 minutes and an elimination half-life of 2 to 4 days. More than 90% of the drug is bound to plasma proteins, and binding may approach 100% during prolonged infusion. Cisplatin does not cross the blood-brain barrier. Excretion is predominantly renal and is incomplete.

Clinical Use

Cisplatin, combined with bleomycin and vinblastine or etoposide, produces cures in most patients with metastatic testicular cancer or germ cell cancer of the ovary. Cisplatin also shows some activity against carcinomas of the head and neck, bladder, cervix, prostate, and lung.

Side effects

Renal toxicity is the major potential toxicity of cisplatin. Severe nausea and vomiting that often accompany cisplatin administration may necessitate hospitalization. Cisplatin has mild bone marrow toxicity, yielding both leukopenia and thrombocytopenia. Anemia is common and may require transfusions of red blood cells. Anaphylactic allergic reactions have been described. Hearing loss in the high frequencies (4000 Hz) may occur in 10 to 30% of patients. Other reported toxicities include peripheral neuropathies with paresthesias, leg weakness, and tremors. Excessive urinary excretion of magnesium also may occur.

Safety Profile

Confirmed carcinogen with experimental carcinogenic and tumorigenic data. Poison by ingestion, intramuscular, submtaneous, intravenous, and intraperitoneal routes. Human systemic effects: change in audttory acuity, change in kidney tubules, changes in bone marrow, corrosive to skin, depressed renal function tests, hallucinations, nausea or vomiting. Experimental teratogenic and reproductive effects. Human mutation data reported. When heated to decomposition it emits very toxic fumes of Cland NOx. See also PLATINUM COMPOUNDS.

Synthesis

Cisplatin, cis-diaminodichloroplatinum (30.2.5.1), is made by reducing potassium hexachloroplatinate by hydrazine to potassium tetrachloroplatinate, which reacts with ammonia to give cisplatin (30.2.5.1) .

Potential Exposure

A potential danger to those involved in the manufacture, formulation and administration of this anticancer chemotherapy agent. Contact with water causes decomposition.

Veterinary Drugs and Treatments

In veterinary medicine, the systemic use of cisplatin is presently limited to use in dogs. The drug has been, or may be, useful in a variety of neoplastic diseases including squamous cell carcinomas, transitional cell carcinomas, ovarian carcinomas, mediastinal carcinomas, osteosarcomas, pleural adenocarcinomas, nasal carcinomas, and thyroid adenocarcinomas.
Cisplatin may be useful for the palliative control of neoplastic pulmonary effusions after intracavitary administration.
In horses, cisplatin has been used for intralesional injection for skin tumors.

Drug interactions

Potentially hazardous interactions with other drugs
Aldesleukin: avoid concomitant use.
Antibacterials: increased risk of nephrotoxicity and possibly ototoxicity with aminoglycosides, capreomycin, polymyxins or vancomycin.
Antipsychotics: avoid with clozapine, increased risk of agranulocytosis.
Cytotoxics: increased risk of ototoxicity with ifosfamide; increased pulmonary toxicity with bleomycin and methotrexate.

First aid

If this chemical gets into the eyes, remove anycontact lenses at once and irrigate immediately for at least15 min, occasionally lifting upper and lower lids. Seek medical attention immediately. If this chemical contacts theskin, remove contaminated clothing and wash immediatelywith soap and water. Seek medical attention immediately. Ifthis chemical has been inhaled, remove from exposure,begin rescue breathing (using universal precautions, including resuscitation mask) if breathing has stopped and CPR ifheart action has stopped. Transfer promptly to a medicalfacility. When this chemical has been swallowed, get medical attention. Give large quantities of water and inducevomiting. Do not make an unconscious person vomit.

Carcinogenicity

Cisplatin is reasonably anticipated to be a human carcinogen based on sufficient evidence of carcinogenicity from studies in experimental animals.

Metabolism

It is rapidly hydrated, resulting in a short plasma half-life of less than 30 minutes. It is eliminated predominantly via the kidney, but approximately 10% of a given dose undergoes biliary excretion. It is highly nephrotoxic and can cause significant damage to the renal tubules, especially in patients with preexisting kidney disease or one kidney or who are concurrently receiving other nephrotoxic drugs (e.g., cyclophosphamide or ifosfamide). Dosages should be reduced in any of the above situations. Clearance decreases with chronic therapy, and toxicities can manifest at a late date. To proactively protect patients against kidney damage, patients should be hydrated with chloride-containing solutions. Saline or mannitol diuretics can be administered to promote continuous excretion of the drug and its hydrated analogues. Sodium thiosulfate, which accumulates in the renal tubules, also has been used to neutralize active drug in the kidneys in an effort to avoid nephrotoxicity.

storage

Room temperature

Shipping

UN2928 Toxic solids, corrosive, organic, n.o.s., Hazard Class: 6.1; Labels: 6.1-Poisonous materials, 8-Corrosive material, Technical Name Required. UN3290 Toxic solid, corrosive, inorganic, n.o.s., Hazard class: 6.1; Labels: 6.1-Poisonous materials, 8-Corrosive material. UN3288 Toxic solids, inorganic, n.o.s., Hazard Class: 6.1; Labels: 6.1-Poisonous materials, Technical Name Required. UN3249 Medicine, solid, toxic, n.o.s., Hazard Class: 6.1; Labels: 6.1-Poisonous materials

Purification Methods

Recrystallise it from dimethylformamide and check the purity by IR and UV-VIS spectroscopy. [Raudaschl et al. Inorg Chim Acta 78 143 1983.] HIGHLY TOXIC, SUSPECTED CARCINOGEN.

Incompatibilities

Aluminum reacts with cisplatin and decreases the drug’s effectiveness. Do not use any aluminum equipment to prepare or administer cisplatin.

Waste Disposal

Disposal of unused product must be undertaken by qualified personnel who are knowledgeable in all applicable regulations and follow all pertinent safety precautions including the use of appropriate protective equipment. For proper handling and disposal, always comply with federal, state, and local regulations

References

1) Van Waardenburg et al. (2004), Platinated DNA adducts enhance poisoning of DNA topoisomerase I by camptothecin; J. Biol. Chem,, 279 54502 DOI:10.1074/JBC.M410103200
2) Siddik et al. (2003), Cisplatin: mode of cytotoxic action and molecular basis of resistance; Oncogene, 22 7265 DOI:10.1038/sj.onc.1206933
3) Seki et al. (2000), Cisplatin (CDDP) specifically induces apoptosis via sequential activation of caspase-8, -3 and -6 in osteosarcoma; Cancer Chemother. Pharmacol., 45 199 DOI:10.1007/s002800050030
4) Nomura et al. (2004), Cisplatin inhibits the expression of X-linked inhibitor of apoptosis protein in human LNCaP cells; Urol. Oncol., 22 453 DOI:10.1016/J.UROLONC.2004.04.035
5) Raghavan et al. (2015), Dimethylsulfoxide inactivates the anticancer effect of cisplatin against myelogenous leukemia cell lines in in vitro assays.; Indian J. Phamracol., 47 322 DOI:10.4103/0253-7613.157132
6) Synthesis of Essential Drugs (2006, Elsevier) - libgen.lc
7) Sittig's Pharmaceutical Manufacturing Encyclopedia
8) Patty's Toxicology 6-Volume Set-Wiley (2012)
9) Modern pharmacology with clinical applications (2004, LWW)

Cisplatin Preparation Products And Raw materials

Raw materials

Preparation Products

Less

Cisplatin Suppliers

Americas 1 Argentina 5 Austria 1 Belgium 3 Brazil 5 Canada 4 China 678 Czech Republic 2 Europe 5 France 5 Germany 17 India 86 Israel 2 Japan 6 Nigeria 1 Philippines 1 Poland 1 Singapore 1 Slovenia 1 South Africa 1 South Korea 3 Switzerland 3 The Netherlands 1 United Kingdom 19 United States 76 Uruguay 1 Global 929

Nanjing Sunlida Biological Technology Co., Ltd.

Tel: 025-57798810
Fax: 025-57019371
Email: sales@sunlidabio.com
Country: China
ProdList: 3239
Advantage: 55

Jinan Yuantai Pharmaceutical Co.,Ltd

Tel: 0531-69959492 18366108822
Fax: 0531-69959492
Email: 85633700@qq.com
Country: China
ProdList: 79
Advantage: 55

Jinan Sunshine Pharmaceutical Co.,Ltd.

Tel: 0531-82812892
Fax: 0531-82812892
Email: sunshinepharm0531@163.com
Country: China
ProdList: 37
Advantage: 58

TargetMol Chemicals Inc.

Tel: 021-021-33632979 15002134094
Fax: 021-33632979
Email: marketing@targetmol.com
Country: China
ProdList: 7782
Advantage: 58

Wuhan penglei Biotechnology Co., Ltd

Tel: 15871464247 17307245989
Email: 3471278124@qq.com
Country: China
ProdList: 4995
Advantage: 58

Jinan New Era Chemical Co., Ltd.

Tel: 0531-84319199 18660131512
Email: 1417934650@qq.com
Country: China
ProdList: 48
Advantage: 58

Jinan Hanyu Chemical Co., Ltd

Tel: 0531-69954981 15666777973
Email: sales@hanyuchem.com
Country: China
ProdList: 66
Advantage: 58

Shandong Platinum Pharmaceutical Co., Ltd.

Tel: 0531-88977029 18396830603
Fax: 0531-88964879
Email: sales@boyuanpharm.com
Country: China
ProdList: 216
Advantage: 58

Shanghai Boyle Chemical Co., Ltd.

Tel
Fax: 86-21-57758967
Email: sales@boylechem.com
Country: China
ProdList: 2922
Advantage: 55

J & K SCIENTIFIC LTD.

Tel: 18210857532; 18210857532
Fax: 86-10-82849933
Email: jkinfo@jkchemical.com
Country: China
ProdList: 96815
Advantage: 76

Sichuan Ruibo Technology Co., Ltd

Tel: +86-817-5586080
Fax: +86-817-5527378
Country: China
ProdList: 42
Advantage: 69

Meryer (Shanghai) Chemical Technology Co., Ltd.

Tel: 4006356688 18621169109
Fax: 86-21-61259102
Email: market03@meryer.com
Country: China
ProdList: 40228
Advantage: 62

3B Pharmachem (Wuhan) International Co.,Ltd.

Tel: 821-50328103-801 18930552037
Fax: 86-21-50328109
Email: 3bsc@sina.com
Country: China
ProdList: 15838
Advantage: 69

Chembest Research Laboratories Limited

Tel: +86-21-20908456
Fax: 021-58180499
Email: sales@BioChemBest.com
Country: China
ProdList: 6003
Advantage: 61

Alfa Aesar

Tel: 400-6106006
Fax: 021-67582001/03/05
Email: saleschina@alfa-asia.com
Country: China
ProdList: 30123
Advantage: 84

TCI (Shanghai) Development Co., Ltd.

Tel: 021-67121386
Fax: 021-67121385
Email: Sales-CN@TCIchemicals.com
Country: China
ProdList: 24529
Advantage: 81

Beijing HwrkChemical Technology Co., Ltd

Tel: 18515581800 18501085097
Fax: 010-89508210
Email: sales.bj@hwrkchemical.com
Country: China
ProdList: 9400
Advantage: 55

Energy Chemical

Tel: 021-021-58432009 400-005-6266
Fax: 021-58436166
Email: sales8178@energy-chemical.com
Country: China
ProdList: 44801
Advantage: 61

Beijing Ouhe Technology Co., Ltd

Tel: 010-010-82967028 13522913783
Fax: +86-10-82967029
Email: 2355560935@qq.com
Country: China
ProdList: 12000
Advantage: 60

Jia Xing Isenchem Co.,Ltd

Tel: 0573-85285100 18627885956
Fax: 0573-85285100
Email: isenchem@163.com
Country: China
ProdList: 9310
Advantage: 66

Adamas Reagent, Ltd.

Tel: 400-6009262 16621234537
Fax: 021-64823266
Email: chenyj@titansci.com
Country: China
ProdList: 14101
Advantage: 59

Nanjing Chemlin Chemical Co., Ltd

Tel: 025-83697070
Fax: +86-25-83453306
Email: info@chemlin.com.cn
Country: China
ProdList: 16075
Advantage: 64

Shanghai Hanhong Scientific Co.,Ltd.

Tel: 021-54306202 13764082696
Email: info@hanhongsci.com
Country: China
ProdList: 42934
Advantage: 64

Chemsky（shanghai）International Co.,Ltd.

Tel: 021-50135380
Email: shchemsky@sina.com
Country: China
ProdList: 32321
Advantage: 50

XiaoGan ShenYuan ChemPharm co,ltd

Tel: 15527621225
Email: 1791901229@qq.com
Country: China
ProdList: 6946
Advantage: 52

Shandong Xiya Chemical Co., Ltd

Tel: 4009903999 13355009207
Fax: 0539-6365991
Email: 3007715519@qq.com
Country: China
ProdList: 18729
Advantage: 57

Sichuan Kulinan Technology Co., Ltd

Tel: 400-1166-196 18981987031
Fax: 028-84555506 800101999
Email: cdhxsj@163.com
Country: China
ProdList: 11705
Advantage: 57

Tianjin heowns Biochemical Technology Co., Ltd.

Tel: 400 638 7771
Email: sales@heowns.com
Country: China
ProdList: 14435
Advantage: 57

Sinopharm Chemical Reagent Co,Ltd.

Tel: 86-21-63210123
Fax: 86-21-63290778 86-21-63218885
Email: sj_scrc@sinopharm.com
Country: China
ProdList: 9815
Advantage: 79

Shanghai Sunway Pharmaceutical Technology Co., Ltd

Tel: 18270980682
Fax: 021 51613951
Email: mlcheng@sunwaypharm.cn
Country: China
ProdList: 8669
Advantage: 57

Nanjing Vital Chemical Co., Ltd.

Tel: Please Send Email 18652950785
Fax: 025-87193546
Email: chemweiao@163.com
Country: China
ProdList: 4378
Advantage: 65

Hangzhou Yuhao Chemical Technology Co., Ltd

Tel: 0571-82693216
Fax: +86-571-82880190
Email: info@yuhaochemical.com
Country: China
ProdList: 6387
Advantage: 52

Shanghai Sphchem Co., Ltd.

Tel: 021-56491756 13512199871
Fax: 021-5649-1756
Email: 2819742715@qq.com
Country: China
ProdList: 4000
Advantage: 55

Spectrum Chemical Manufacturing Corp.

Tel: 021-021-021-67601398-809-809-809 15221380277
Fax: 021-57711696
Email: marketing_china@spectrumchemical.com
Country: China
ProdList: 9658
Advantage: 60

Wuhan Fortuna Chemical Co., Ltd

Tel: 027-59207852 13308628970
Fax: QQ3130921841
Email: buy@fortunachem.com
Country: China
ProdList: 2744
Advantage: 58

Dalian Meilun Biotech Co., Ltd.

Tel: 0411-62910999 13889544652
Email: sales@meilune.com
Country: China
ProdList: 4747
Advantage: 58

ShangHai YuanYe Biotechnology Co., Ltd.

Tel: 021-61312847 13636370518
Fax: 021-55068248
Email: shyysw007@163.com
Country: China
ProdList: 4999
Advantage: 60

Chengdu Ai Keda Chemical Technology Co., Ltd.

Tel: 4008-755-333 18080918076
Fax: 028-86757656
Email: 800078821@qq.com
Country: China
ProdList: 9718
Advantage: 55

T&W GROUP

Tel: 021-61551611 13296011611
Fax: ＋86 21-50676805
Email: contact@trustwe.com
Country: China
ProdList: 9895
Advantage: 58

Shanghai civi chemical technology co.,Ltd

Tel: 86-21-34053660
Fax: 86-21-34053661
Email: sale@labgogo.com
Country: China
ProdList: 9865
Advantage: 52

Thermo Fisher Scientific

Tel: 800-810-5118
Fax: +86-10-84193589
Email: cnchemical@thermofisher.com
Country: China
ProdList: 17770
Advantage: 75

Beijing HuaMeiHuLiBiological Chemical

Tel: 010-56205725
Fax: 010-65763397
Email: waley188@sohu.com
Country: China
ProdList: 12335
Advantage: 58

Beijing innoChem Science & Technology Co.,Ltd.

Tel: 400-810-7969 010-59572699
Fax: 010-59572688
Email: ningzi.li@inno-chem.com.cn
Country: China
ProdList: 6134
Advantage: 55

Shanghai Topbiochem Technology Co., Ltd

Tel: +86-21-60341587
Fax: +86-21-61294319
Email: sales@topbiochem.com
Country: China
ProdList: 6175
Advantage: 58

NCE Biomedical Co.,Ltd.

Tel: 4000-027-021 |24 +86-13986109188 | +86-15623472865 | +81-08033611988
Fax: +86-27-87599188
Country: China
ProdList: 1493
Advantage: 55

Shanghai T&W Pharmaceutical Co., Ltd.

Tel: +86 21 61551611
Fax: +86 21 50676805
Country: China
ProdList: 9891
Advantage: 58

Shanghai Jian Chao Chemical Technology Co., Ltd.

Tel: 150-2103-5486 18017383231
Fax: qq：2817624287
Email: 983544897@qq.com
Country: China
ProdList: 9342
Advantage: 55

Haoyuan Chemexpress Co., Ltd.

Tel: 021-58950125
Fax: (86) 21-58955996
Email: info@chemexpress.com
Country: China
ProdList: 7552
Advantage: 61

Candia Thamtech Company Limited

Tel: 0371-86615086 18203638366 0371-86159066 13526786601
Fax: 0371-86159066
Country: China
ProdList: 2015
Advantage: 60

9ding chemical ( Shanghai) Limited

Tel: 4009209199
Fax: 86-021-52271987
Email: sales@9dingchem.com
Country: China
ProdList: 22514
Advantage: 55

Less

View Lastest Price from Cisplatin manufacturers

Shaanxi Dideu Medichem Co. Ltd

Product: Cisplatin 15663-27-1
Price: US $50.00-13.00/KG
Min. Order: 1KG
Purity: 99%
Supply Ability: 200000KG
Release date: 2025-09-03

WUHAN FORTUNA CHEMICAL CO., LTD

Product: Cisplatin 15663-27-1
Price: US $0.00/g
Min. Order: 10g
Purity: 97%-102%; EP
Supply Ability: 1000g
Release date: 2022-12-29

Hebei Chuanghai Biotechnology Co., Ltd

Product: Cisplatin 15663-27-1
Price: US $0.00/KG
Min. Order: 1KG
Purity: 99%
Supply Ability: 100 MT
Release date: 2024-11-26

15663-27-1, CisplatinRelated Search:

Oxaliplatin Carboplatin VANADIUM(III) ACETYLACETONATE Tetrakis(triphenylphosphine)palladium Bis(diphenylphosphinophenyl)ether palladium (II) dichloride Cisplatin Injection CIS-DIAMMINEDICHLOROPLATINUM(II),TRANS-DIAMMINEDICHLOROPLATINUM(II),trans-diamminedichloroplatinu carboquone Palladium Platinum DIAMMINE PLATINUM(Ⅱ) CHLORIDE Cisplatin cisplatin-deoxy(adenosine monophosphate guanosine) adduct CIS-DIAMMINEDICHLOROPLATINUM, (CISPLATIN),CIS-DIAMMINEDICHLOROPLATINUM, (CISPLATIN) deoxyadenylyl-thymidyl-deoxyguanylyl-deoxyguanosine-cisplatin complex cisplatin-deoxy(guanosine monophosphate guanosine) adduct DVP (cisplatin) cisplatin-guanosine adduct

LEDERPLATIN

BRIPLATIN

DIAMMINEDICHLOROPLATINATE (II)

CPDC

CISMAPLAT

CISPLATIIN

CISPLATIN DIHYDROCHLORIDE

CISPLATIN

CIS PT(NH3)2CL2

CISPLATYL

CIS-PLATINUM(II)DIAMMINE DICHLORIDE

CIS-PLATINUM(II)DIAMINE DIHYDROCHLORIDE

CIS-PLATINUM

CIS-DDP

CIS-DIAMINODICHLOROPLATINUM

CIS-DIAMINEDICHLOROPLATINUM

CIS-DIAMMINEDICHLORPLATINE

CIS-DIAMMINEDICHLOROPLATINUM(II)

CIS-DIAMMINEPLATINUM (II) CHLORIDE

CIS-DIAMMINEPLATINUM(II) DICHLORIDE

CIS-DICHLORODIAMMINEPLATINUM(II), 99.999 %

CIS-DIAMMINEDICHLOROPLATINUM(II), 99.9+%

CIS-DIAMMINEDICHLOROPLATINUM(II) CISPLATIN , 99+% USP BP EP

Cisplatinusp28

Cisplatin99%

Briplatin, Cismaplat, Cisplatyl, Lederplatin, Neoplatin, Platamine, Platinex, Platiblastin, Platinol, Platinoxan,

cis-Diammineplatinum(II)dichloride (cisplatine)

cis-Dichlorodiammineplatinum(II),99%

CISPLATIN,USP

CIS-DIAMINE-DICHLOROPLATINIUMII

CIS-DIAMINECHLOROPLATINUM

CIS-DICHLORDIAMINOPLATINUM

CIS-DIAMINECHLOROPLATINUM(II)

CISPLATIN (PLATINOL, DDP, PDD)

NEOPLATIN

PLATIBLASTIN

PLATINEX

PLATINOXAN

PLATINOL

PLATAMINE

PLATINUM DIAMMINO DICHLORIDE

cis-Platinum(II) diammine chloride

DichlorodiammineplatinumIIyelloworangextl

Platinumdiamminechloride

cis-Dichlorodiamineplatinum(II), 99.99%

cis-DIAMMINEPLATINUM (II) CHLORIDE 99.999%

trans-dichlorodiaMMine platinuM(II) Cl2H6N2Pt, β

cis-DiaMMineplatinuM dichloride

CIS-PLATINUM (65% PT)

cis-Diamineplatinum(Ⅱ) dichloride

cis-DiaMineplatinuM(II) dichloride >=99.9% trace Metals basis

Platinum, diamminedichloro-, (SP-4-2)-

Cisplatin, >=98%

Cispalatin

cis-Platinum (65% Pt) for synthesis

cis-Dichlorodiammine platinum(II), 99% CISPLATIN

Dichlorodiammineplatinum

cis-Dichlorodiammineplatinum (II), CISPLATIN (USP)